Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

This 52‐week, randomized, double‐blind study compared the efficacy and safety of metformin plus pioglitazone with the established combination of metformin plus gliclazide in type 2 diabetes mellitus.

[1]  C. Bailey,et al.  The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. , 1999, Drugs.

[2]  M. Kipnes,et al.  Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. , 2001, The American journal of medicine.

[3]  R. DeFronzo.  Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[4]  J. Gerich.  Oral hypoglycemic agents. , 1989, The New England journal of medicine.

[5]  S. Marso.  Optimizing the diabetic formulary: beyond aspirin and insulin. , 2002, Journal of the American College of Cardiology.

[6]  S. Aronoff,et al.  Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.

[7]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[8]  L. S. Hermann,et al.  Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. , 1995, Diabetes care.

[9]  M. Laakso,et al.  Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. , 1995, Circulation.

[10]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[11]  J. Frohlich,et al.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[12]  M. Tan.  Current treatment of insulin resistance in type 2 diabetes mellitus. , 2000, International journal of clinical practice. Supplement.

[13]  E. Stein.  Laboratory surrogates for anti-atherosclerotic drug development. , 2001, The American journal of cardiology.

[14]  M. Matsuda,et al.  Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. , 2001, Diabetes care.

[15]  G. Charpentier.  Oral combination therapy for type 2 diabetes , 2002, Diabetes/metabolism research and reviews.

[16]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[17]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[18]  M. D. Leibowitz,et al.  Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. , 1996, Biochemical and biophysical research communications.

[19]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[20]  R. DeFronzo,et al.  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.

[21]  J. Frohlich,et al.  The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). , 2001, Clinical biochemistry.

[22]  G. Charpentier,et al.  Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[23]  L. J. Hardies,et al.  Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. , 2003, Diabetes.

[24]  D. Einhorn,et al.  Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. , 2000, Clinical therapeutics.

[25]  Shao-min Song.  The role of increased liver triglyceride content: a culprit of diabetic hyperglycaemia? , 2002, Diabetes/metabolism research and reviews.

[26]  M. D. Leibowitz,et al.  Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2 , 1996 .

[27]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[28]  Curt D. Furberg,et al.  Coronary Heart Disease in Patients With Low LDL-Cholesterol Benefit of Pravastatin in Diabetics and Enhanced Role for HDL-Cholesterol and Triglycerides as Risk Factors , 2002 .

[29]  F. Ovalle,et al.  Clinical evidence of thiazolidinedione‐induced improvement of pancreatic β‐cell function in patients with type 2 diabetes mellitus , 2002, Diabetes, obesity & metabolism.

[30]  B. Howard,et al.  LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study. , 1999, Diabetes care.

[31]  B. Sobel,et al.  Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. , 2002, Diabetes care.

[32]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.